Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): January 11, 2021



(Exact Name of Registrant as Specified in its Charter)




Delaware   001-39531   45-1539785

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


7380 Coca Cola Drive, Suite 106,

Hanover, Maryland, 27106

(Address of Principal Executive Offices) (Zip Code)


Registrant’s telephone number, including area code: (443) 776-3133


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value per share   PCSA   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company [  ]


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]






Item 7.01. Regulation FD Disclosure.


Processa Pharmaceuticals, Inc. (“Processa”) will participate in virtual meetings with analysts and investors beginning January 11, 2021 and through the conclusion of the H.C. Wainwright Bioconnect 2021 Conference January 14, 2021. During these meetings, Processa will use a presentation handout, which is attached as Exhibit 99.2 to this Current Report on Form 8-K. The presentation handout will also be made available in the “Investors” section on Processa’s website, located at processapharmaceuticals.com.


Processa undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time through the filing of other reports or documents with the Securities Exchange Commission, through press releases, or through other public disclosure, including in the “Investors” section of Processa’s website. Processa routinely uses its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.


The information in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.


Item 9.01. Financial Statements and Exhibits.







Press Release Issued on January, 11 2021

99.2   January 2021 Corporate Presentation Handout






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: January 11, 2021 By: /s/ David Young
    David Young
    Chief Executive Officer



Processa Pharmaceuticals (QB) (USOTC:PCSA)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Processa Pharmaceuticals (QB) Charts.
Processa Pharmaceuticals (QB) (USOTC:PCSA)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Processa Pharmaceuticals (QB) Charts.